Evidence map›Paper›PMID 33819029›Full record

ArticleAnalytical chemistry2021

Multiplexed Signal Ion Emission Reactive Release Amplification (SIERRA) Assay for the Culture-Free Detection of Gram-Negative and Gram-Positive Bacteria and Antimicrobial Resistance Genes.

Michael Pugia, Tiyash Bose, Marco Tjioe, Dylan Frabutt, Zane Baird, Zehui Cao, Anna Vorsilak, Ian McLuckey, M Regina Barron, Monica Barron and 7 more

Open access · greenAbstract read
In one paragraph

Article in Analytical chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Michael PugiaBioanalytical Technologies, Indiana Biosciences Research Institute (IBRI), 1345 W. 16th Street, Suite #300, Indianapolis, Indiana 46202, United States.
Tiyash BoseBioanalytical Technologies, Indiana Biosciences Research Institute (IBRI), 1345 W. 16th Street, Suite #300, Indianapolis, Indiana 46202, United States.
Marco TjioeBioanalytical Technologies, Indiana Biosciences Research Institute (IBRI), 1345 W. 16th Street, Suite #300, Indianapolis, Indiana 46202, United States.
Dylan FrabuttBioanalytical Technologies, Indiana Biosciences Research Institute (IBRI), 1345 W. 16th Street, Suite #300, Indianapolis, Indiana 46202, United States.
Zane BairdBioanalytical Technologies, Indiana Biosciences Research Institute (IBRI), 1345 W. 16th Street, Suite #300, Indianapolis, Indiana 46202, United States.ORCID 0000-0001-5725-0375
Zehui CaoBioanalytical Technologies, Indiana Biosciences Research Institute (IBRI), 1345 W. 16th Street, Suite #300, Indianapolis, Indiana 46202, United States.
Anna VorsilakBioanalytical Technologies, Indiana Biosciences Research Institute (IBRI), 1345 W. 16th Street, Suite #300, Indianapolis, Indiana 46202, United States.
Ian McLuckeyBioanalytical Technologies, Indiana Biosciences Research Institute (IBRI), 1345 W. 16th Street, Suite #300, Indianapolis, Indiana 46202, United States.
M Regina BarronBioanalytical Technologies, Indiana Biosciences Research Institute (IBRI), 1345 W. 16th Street, Suite #300, Indianapolis, Indiana 46202, United States.
Monica BarronBioanalytical Technologies, Indiana Biosciences Research Institute (IBRI), 1345 W. 16th Street, Suite #300, Indianapolis, Indiana 46202, United States.
Gerald DenysDivision of Clinical Microbiology, Department of Pathology and Laboratory Medicine, IU Health Pathology Laboratory, Indiana University School of Medicine, 350 W. 11th Street, Room 6027B, Indianapolis, Indiana 46202, United States.
Jessica CarpenterDivision of Clinical Microbiology, Department of Pathology and Laboratory Medicine, IU Health Pathology Laboratory, Indiana University School of Medicine, 350 W. 11th Street, Room 6027B, Indianapolis, Indiana 46202, United States.
Amitava DasIndiana Center for Regenerative Medicine and Engineering (ICRME), IU Health Comprehensive Wound Center, Department of Surgery, Indiana University School of Medicine, 975 W. Walnut Street, Suite #444, Indianapolis, Indiana 46202,United States.
Karamjeet KaurIndiana Center for Regenerative Medicine and Engineering (ICRME), IU Health Comprehensive Wound Center, Department of Surgery, Indiana University School of Medicine, 975 W. Walnut Street, Suite #444, Indianapolis, Indiana 46202,United States.
Sashwati RoyIndiana Center for Regenerative Medicine and Engineering (ICRME), IU Health Comprehensive Wound Center, Department of Surgery, Indiana University School of Medicine, 975 W. Walnut Street, Suite #444, Indianapolis, Indiana 46202,United States.
Chandan K SenIndiana Center for Regenerative Medicine and Engineering (ICRME), IU Health Comprehensive Wound Center, Department of Surgery, Indiana University School of Medicine, 975 W. Walnut Street, Suite #444, Indianapolis, Indiana 46202,United States.
Frédérique DeissDepartment of Chemistry & Chemical Biology, Indiana University-Purdue University Indianapolis (IUPUI), 402 N Blackford Street, LD326, Indianapolis, Indiana 46202, United States.ORCID 0000-0002-8626-5370
Indiana Biosciences Research Institute · USIndiana University Health · USIndiana University – Purdue University Indianapolis · US

Funding

Diabetic Foot Ulcer Biofilm Infection and RecurrenceR01DK125835 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GURTNER, GEOFFREY C, SEN, CHANDAN K · 2020 to 2024
$3.5M
Wound Healing Endpoint and RecurrenceR01NR015676 · NINR · OHIO STATE UNIVERSITY · PI GORDILLO, GAYLE M, ROY, SASHWATI · 2015 to 2019
$2.6M
Mechanisms Underlying Impaired Diabetic Wound HealingR01DK114718 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI ROY, SASHWATI · 2018 to 2021
$1.6M
NIDDK NIH HHS R01 DK114718NIDDK NIH HHS R01 DK125835NINR NIH HHS R01 NR015676
6 · The paper itself

Abstract

The global prevalence of antibiotic-resistant bacteria has increased the risk of dangerous infections, requiring rapid diagnosis and treatment. The standard method for diagnosis of bacterial infections remains dependent on slow culture-based methods, carried out in central laboratories, not easily extensible to rapid identification of organisms, and thus not optimal for timely treatments at the point-of-care (POC). Here, we demonstrate rapid detection of bacteria by combining electrochemical immunoassays (EC-IA) for pathogen identification with confirmatory quantitative mass spectral immunoassays (MS-IA) based on signal ion emission reactive release amplification (SIERRA) nanoparticles with unique mass labels. This diagnostic method uses compatible reagents for all involved assays and standard fluidics for automatic sample preparation at POC. EC-IA, based on alkaline phosphatase-conjugated pathogen-specific antibodies, quantified down to 10

Indexed as

Anti-Bacterial AgentsAnti-Infective AgentsDrug Resistance, BacterialEscherichia coliGram-Negative BacteriaGram-Positive BacteriaHumansMicrobial Sensitivity TestsStaphylococcus aureusAnti-Bacterial AgentsAnti-Infective Agents

Identifiers

PMID33819029
PMCPMC9097648
OpenAlexW3145191142

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.